Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve Them
Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.
Gen Li, PhD, MBA
Advertisement
Articles by Gen Li, PhD, MBA
Pharmaceutical Executive
A discussion of the cost and time put into clinical trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer Receives Unsolicited Mini-Tender Offer for 1 Million Shares from Tutanota: Report
2
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
3
How Do Recent Actions from FDA Provide Insight to the Agency's Enforcement Posture?
4
Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer
5